Recovering scientist turned early stage VC A biotech optimist fighting gravity

A Biotech Midsummer’s Madness
August 21, 2024

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC Greetings from Lake Winnipesaukee in NH where I am at this time every year. It’s midsummer and vacation time for me and the

Leave a comment

Medicinal Chemistry In The Age Of Artificial Intelligence
August 5, 2024

By Peter Tummino, CSO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC  “Over the next five to 10 years, our goal is to become a company that’s leading the world in personalized medicines, a company

Leave a comment

A Primer on Early-Stage Biotech VC
July 31, 2024

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC From the outside, one might assume all biotech venture capital (VC) firms are more similar than different. However, once you look under the

Leave a comment

Looking for Opportunities to Accelerate Clinical Research in Rare Diseases
July 17, 2024

By Mike Cloonan, Chief Executive Officer of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC The drug development process in rare diseases is rife with challenges especially when companies target significant differentiation or first-in-class targets. Identifying

Leave a comment

A Molecular Biologist’s Advice For Life
July 1, 2024

Having just turned 50, I’ve been reflecting on my first half-century of late… many fun and impactful moments, a few regrets, and a life I’ve tried to live to the fullest. One thread that has run throughout it has been

Leave a comment

To B or Not to (Series) B
June 18, 2024

By Robert Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC Strategic considerations of when and how to consider raising additional capital to support clinical development in an improving but still volatile market. As

Leave a comment

Neuro-Immunology: The Promise Of A Differentiated Approach To Neurodegenerative Disease
June 5, 2024

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC In the last decade, our industry has made great strides in combating cancer by harnessing the body’s own immune system. As it was

Leave a comment

Boiling It Down: Conveying Complexity For Decision-makers
May 22, 2024

By Ankit Mahadevia, former CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Drug development is complex. So is running a business. Sometimes, the work of doing both can make your head spin. In my

Leave a comment

Has Spring Sprouted New Growth in Immuno-Oncology?
May 9, 2024

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC As Boston’s weather has started its turn from the frigid darkness that is a northeast winter to the longer days and lighter conditions

Leave a comment

Mariana Oncology’s Radiopharm Platform Acquired By Novartis
May 6, 2024

Novartis recently announced the acquisition of Mariana Oncology, an emerging biotech focused on advancing a radioligand therapeutics platform, for up to $1.75 billion in upfronts and future milestones. The capstone of its three short years of operations, this acquisition represents

Leave a comment

Stars and Scars… Some Lessons Learned About Leadership
May 2, 2024

By Arthur O. Tzianabos, PhD, CEO of Lifordi Immunotherapeutics, as part of the From the Trenches feature of LifeSciVC As the biotech industry continues to pick up steam, I have been getting a number of phone calls from folks in

Leave a comment

The Biotech Startup Contraction Continues… And That’s A Good Thing
April 26, 2024

Venture creation in biotech is witnessing a sustained contraction. After the pandemic bubble’s over-indulgence, the venture ecosystem appears to have reset its pace of launching new startups. According to the latest Pitchbook data, venture creation in biotech hit its slowest

Leave a comment



Verified by ExactMetrics